Dr. Maciej Lesniak interview

A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:

Folder: MultiVuVideo

Uploaded: Jun 22, 2017

Views: 23

Likes: 1

Tags: FDA, brain, cancer, health, healthcare, treatment, Medicine, glioma, MultiVu, 7944251

published 1 year ago